PA
Pacific Biosciences of California, Inc.
PACB · NASDAQ
$1.32 -0.75% (-$0.01)
1M +17.39%
Market Cap $419.3M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$1.72
30.3% upside
Current Price
$1.32
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PACB is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
64 /100
Fair P/S 2.63x
EV/FFO N/A
P/B N/A
Growth
44 /100
Stable Book val. growth 78.82%
Rev. growth 7.64%
FCF growth N/A
Profitability
14 /100
Weak Net margin 82.49%
Op. margin 102.05%
FCF margin 107.46%
Quality
4 /100
Poor ROA 17.48%
Asset turnover 0.21x
ROIC 23.90%
Debt
43 /100
Moderate Int. coverage -32.92x
Current ratio 4.92x
Net debt/EBITDA N/A
Stability
14 /100
Unstable Rev. volatility 40.41%
EPS volatility 47.74%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PACB
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Mark Van Oene
Employees
485
Headquarters
Menlo Park
Upcoming events
03 NOV
Earnings
Upcoming earnings report
09 FEB
Earnings
Upcoming earnings report